Natera Sues Sequenom over Noninvasive Prenatal Diagnosis IP | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Prenatal diagnostics company Natera has sued Sequenom, claiming that it does not infringe a patent on noninvasive prenatal diagnosis methods held by Sequenom.

The suit also claims that the patent in question, US Patent No. 6,258,540, entitled "Non-invasive prenatal diagnosis," is invalid.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.